RIRs and 95% CIs for male volunteer firefighters who attended incidents to 31 December 2010 by number of incidents and incident types (adjusted for age and calendar period)
| Cancer categories | Groups* | O | All incidents | O | All fire incidents | O | Structural fire incidents | O | Landscape fire incidents | O | Vehicle fire incidents |
| All malignancies | Baseline | 4184 | Ref | 4191 | Ref | 4283 | Ref | 3566 | Ref | 4191 | Ref |
| Group 2 | 210 | 1.09 (0.95 to 1.26) | 217 | 1.09 (0.95 to 1.25) | 142 | 1.20 (1.01 to 1.42) | 681 | 1.07 (0.98 to 1.16) | 218 | 1.08 (0.94 to 1.24) | |
| Group 3 | 97 | 1.05 (0.86 to 1.28) | 83 | 1.02 (0.82 to 1.27) | 66 | 1.08 (0.84 to 1.37) | 244 | 1.05 (0.92 to 1.19) | 82 | 1.06 (0.85 to 1.31) | |
| Lip, oral cavity and pharynx | Baseline | 151 | Ref | 151 | Ref | 154 | Ref | 129 | Ref | 153 | Ref |
| Group 2 | 7 | 1.03 (0.48 to 2.19) | 7 | 1.01 (0.47 to 2.16) | 3 | 0.70 (0.22 to 2.20) | 25 | 1.11 (0.72 to 1.71) | 6 | 0.82 (0.36 to 1.84) | |
| Group 3 | 1 | 0.31 (0.04 to 2.25) | 1 | 0.37 (0.05 to 2.64) | 2 | 0.96 (0.24 to 3.88) | 5 | 0.66 (0.27 to 1.60) | 0 | – | |
| Digestive organs | Baseline | 750 | Ref | 753 | Ref | 773 | Ref | 627 | Ref | 754 | Ref |
| Group 2 | 49 | 1.42 (1.06 to 1.89) | 48 | 1.33 (0.99 to 1.78) | 29 | 1.35 (0.93 to 1.96) | 138 | 1.22 (1.02 to 1.47) | 43 | 1.18 (0.87 to 1.61) | |
| Group 3 | 9 | 0.54 (0.28 to 1.04) | 7 | 0.47 (0.23 to 1.00) | 6 | 0.54 (0.24 to 1.20) | 43 | 1.03 (0.75 to 1.40) | 11 | 0.79 (0.43 to 1.43) | |
| Colorectal | Baseline | 517 | Ref | 518 | Ref | 530 | Ref | 429 | Ref | 519 | Ref |
| Group 2 | 32 | 1.35 (0.94 to 1.93) | 33 | 1.33 (0.94 to 1.89) | 21 | 1.43 (0.92 to 2.21) | 96 | 1.25 (1.00 to 1.56) | 31 | 1.24 (0.87 to 1.79) | |
| Group 3 | 4 | 0.35 (0.13 to 0.94) | 2 | 0.20 (0.05 to 0.80) | 2 | 0.26 (0.07 to 1.05) | 28 | 0.98 (0.67 to 1.44) | 3 | 0.31 (0.10 to 0.98) | |
| Respiratory | Baseline | 247 | Ref | 246 | Ref | 252 | Ref | 218 | Ref | 248 | Ref |
| Group 2 | 9 | 0.79 (0.41 to 1.54) | 12 | 1.01 (0.57 to 1.81) | 7 | 1.01 (0.48 to 2.14) | 29 | 0.74 (0.50 to 1.09) | 9 | 0.76 (0.39 to 1.47) | |
| Group 3 | 7 | 1.27 (0.60 to 2.69) | 5 | 1.03 (0.42 to 2.49) | 4 | 1.09 (0.41 to 2.93) | 16 | 1.08 (0.65 to 1.80) | 6 | 1.31 (0.58 to 2.95) | |
| Lung | Baseline | 214 | Ref | 213 | Ref | 218 | Ref | 186 | Ref | 215 | Ref |
| Group 2 | 8 | 0.81 (0.40 to 1.65) | 11 | 1.07 (0.58 to 1.96) | 7 | 1.17 (0.55 to 2.49) | 27 | 0.81 (0.54to 1.21) | 9 | 0.88 (0.45 to 1.71) | |
| Group 3 | 6 | 1.26 (0.56 to 2.84) | 4 | 0.95 (0.35 to 2.56) | 3 | 0.95 (0.30 to 2.95) | 15 | 1.18 (0.70 to 2.00) | 4 | 1.01 (0.38 to 2.73) | |
| Melanoma | Baseline | 558 | Ref | 559 | Ref | 570 | Ref | 486 | Ref | 558 | Ref |
| Group 2 | 18 | 0.71 (0.45 to 1.14) | 17 | 0.67 (0.41 to 1.08) | 13 | 0.82 (0.47 to 1.42) | 80 | 0.95 (0.75 to 1.20) | 23 | 0.85 (0.56 to 1.30) | |
| Group 3 | 14 | 1.20 (0.71 to 2.04) | 14 | 1.42 (0.83 to 2.41) | 7 | 0.92 (0.44 to 1.93) | 24 | 0.86 (0.57 to 1.29) | 9 | 0.89 (0.46 to 1.72) | |
| Male reproductive | Baseline | 1659 | Ref | 1664 | Ref | 1699 | Ref | 1408 | Ref | 1657 | Ref |
| Group 2 | 80 | 1.04 (0.83 to 1.30) | 77 | 0.95 (0.75 to 1.19) | 52 | 1.10 (0.83 to 1.45) | 276 | 1.08 (0.94 to 1.22) | 87 | 1.08 (0.87 to 1.34) | |
| Group 3 | 38 | 1.00 (0.73 to 1.38) | 36 | 1.06 (0.77 to 1.48) | 26 | 1.03 (0.70 to 1.51) | 93 | 0.95 (0.77 to 1.17) | 33 | 1.05 (0.74 to 1.48) | |
| Prostate | Baseline | 1578 | Ref | 1581 | Ref | 1615 | Ref | 1337 | Ref | 1577 | Ref |
| Group 2 | 77 | 1.04 (0.83 to 1.31) | 76 | 0.97 (0.77 to 1.23) | 52 | 1.15 (0.87 to 1.52) | 264 | 1.07 (0.94 to 1.22) | 83 | 1.08 (0.87 to 1.35) | |
| Group 3 | 38 | 1.04 (0.75 to 1.43) | 36 | 1.10 (0.79 to 1.53) | 26 | 1.06 (0.72 to 1.57) | 92 | 0.97 (0.78 to 1.19) | 33 | 1.09 (0.77 to 1.54) | |
| Testis | Baseline | 78 | Ref | 80 | Ref | 81 | Ref | 69 | Ref | 77 | Ref |
| Group 2 | 3 | 0.94 (0.30 to 2.97) | 1 | 0.33 (0.05 to 2.35) | 0 | – | 11 | 1.16 (0.61 to 2.21) | 4 | 1.13 (0.42 to 3.10) | |
| Group 3 | 0 | – | 0 | – | 0 | – | 1 | 0.41 (0.06 to 2.99) | 0 | – | |
| Urinary tract | Baseline | 187 | Ref | 184 | Ref | 188 | Ref | 154 | Ref | 187 | Ref |
| Group 2 | 12 | 1.40 (0.78 to 2.52) | 17 | 1.95 (1.18 to 3.20) | 10 | 1.94 (1.03 to 3.66) | 35 | 1.27 (0.88 to 1.84) | 15 | 1.68 (0.99 to 2.84) | |
| Group 3 | 6 | 1.47 (0.65 to 3.31) | 4 | 1.13 (0.42 to 3.06) | 7 | 2.63 (1.24 to 5.59) | 16 | 1.59 (0.95 to 2.67) | 3 | 0.88 (0.28 to 2.74) | |
| Kidney | Baseline | 115 | Ref | 114 | Ref | 116 | Ref | 91 | Ref | 114 | 1 |
| Group 2 | 9 | 1.70 (0.86 to 3.34) | 12 | 2.22 (1.22 to 4.02) | 7 | 2.15 (1.00 to 4.62) | 26 | 1.58 (1.02 to 2.45) | 13 | 2.34 (1.32 to 4.16) | |
| Group 3 | 6 | 2.37 (1.04 to 5.38) | 4 | 1.84 (0.68 to 4.99) | 7 | 4.23 (1.97 to 9.08) | 13 | 2.24 (1.25 to 4.01) | 3 | 1.41 (0.45 to 4.44) | |
| Lymphohaematopoetic | Baseline | 391 | Ref | 392 | Ref | 400 | Ref | 336 | Ref | 393 | 1 |
| Group 2 | 24 | 1.36 (0.90 to 2.05) | 24 | 1.32 (0.87 to 1.99) | 18 | 1.65 (1.03 to 2.64) | 63 | 1.08 (0.82 to 1.41) | 22 | 1.17(0.76 to 1.80) | |
| Group 3 | 11 | 1.32 (0.72 to 2.40) | 10 | 1.38 (0.74 to 2.58) | 8 | 1.45 (0.72 to 2.92) | 27 | 1.29 (0.87 to 1.91) | 11 | 1.55 (0.85 to 2.83) | |
| NHL | Baseline | 168 | Ref | 169 | Ref | 172 | Ref | 144 | Ref | 169 | 1 |
| Group 2 | 10 | 1.30 (0.69 to 2.47) | 11 | 1.39 (0.75 to 2.56) | 8 | 1.67 (0.82 to 3.40) | 28 | 1.09 (0.73 to 1.64) | 9 | 1.10 (0.56 to 2.16) | |
| Group 3 | 3 | 0.82 (0.26 to 2.58) | 1 | 0.32 (0.04 to 2.25) | 1 | 0.42 (0.06 to 2.97) | 9 | 1.00 (0.51 to 1.96) | 3 | 0.96 (0.31 to 3.02) |
NHL, non-Hodgkin lymphoma; O, observed; RIR, relative cancer incident ratio.
*Cut points are based on the tertiles of cumulative incidents for paid firefighters (see online supplementary table S1).